阿魏酸钠治疗糖尿病肾病的初步临床观察

目的探讨阿魏酸钠(sodium ferulate，SF)对糖尿病肾病(diabetic nephropathy，DN)的影响。方法早期DN48例和临床DN54例，随机分为常规治疗组和阿魏酸钠治疗组，测定尿白蛋白排泄率(urinary albumin excretion rates，UAER)、血浆内皮素(serum endothelin，ET)、血尿素氮(blood urea nitrogen，BUN)、血清肌酐(serum creatinine，SCr)和空腹血糖(fasting blood glucose，FBG)，比较两组效果。结果治疗4周后，阿魏酸钠治疗组早期DN和临床DN治疗后UAER、BUN和血ET水平均显著下降(P<0．05，P<0．01)，而常规治疗组UAER、BUN和血ET水平治疗前后差异无显著性。结论阿魏酸钠能降低DN患者UAER和BUN，其机制可能与其减少ET的生成或拮抗ET与其受体结合有关。

Preliminary Clinical Observation on Effect of Soduim Ferulate in Treating Diabetic Nephropathy

ObjectiveTo investigate the effect of sodium ferulate (SF) on diabetic nephropathy (DN). MethodsForty-eight DN patients of early stage and 54 DN patients of clinical stage were randomly divided into two groups, the conventional treatment group and the SF treatment group. Indexes, including urinary albumin excretion rate (UAER), serum endothelin (ET), blood urea nitrogen (BUN), serum creatinine (Scr) and fasting blood glucose (FBG) were observed. ResultsThe levels of UAER, BUN and ET were decreased in all DN patients, either early stage or clinical stage, after treated with SF for 4 weeks (P<0.05, P<0.01), but changed insignificantly in those treated with conventional treatment. ConclusionSF can decrease the levels of UAER and BUN in DN patients, the mechanism may relate with the decreasing of ET production and antagonizing to the binding of ET with its receptors.